Vaccinex Rallies After Announcing Multi-Project Pact Using Its Antibody Discovery Platform

by Vandana Singh, Benzinga Editor

February 19, 2021 8:29 AM | 1 min read

Vaccinex Inc (NASDAQ: VCNX) jumps premarket in reaction to multi-project deals signed with two undisclosed prominent pharmaceutical companies, utilizing Vaccinex's ActivMAb, antibody discovery, and novel viral display platform for antibody discovery against complex antigens such as GPCRs and ion channels.
The financial terms of the deals were not disclosed.
ActivMAb was developed by Vaccinex and is a proprietary mammalian cell-based antibody discovery platform. Applications include discovering antibodies specific for complex membrane antigens and optimized developability and protein optimization for expression and activity.
Price Action: VCNX climbs 50.9% at $4.27 in premarket trading on last check Friday.

Posted In: Biotech News Penny Stocks Contracts General

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.